The key to success is preparation, realistic expectations, and flexibility
GLP-1 drugs such as semaglutide are reshaping treatment of obesity, diabetes and cardiovascular disease with broader physiological effects now emerging
Cosmos Study September 9, 2025 Dual-Team Study Team A:Kersten Bartelt, RNJoe Deckert, PhD Team B:Blaine Franklin, PT, DPTEric Barkley Key Findings At 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight
When I turned 60, I was like: I want to be here for a long time, and I want to look my best
However, in a large study involving people with diabetes who had no comorbidities, GLP-1 RAs were not shown to increase the risk of developing pancreatitis at any time point up through 5 years of use.[ref][ref][ref][ref] The Cleveland Clinic now counsels that GLP-1 RA patients should be screened for pancreatitis risk factors, and a lower dose should be used to reduce the risk of pancreatitis.[ref] Related article : Pancreatitis and Genetic Risk Factors Gastroparesis: Case reports tie semaglutide to a risk of gastroparesis (very slow stomach emptying)
